Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-11-16

FDA Approved: NEOSTIGMINE METHYLSULFATE — Supplemental Application (Amneal Pharmaceuticals LLC)

View source ↗

Summary

FDA approved a supplemental ANDA for Neostigmine methylsulfate by Amneal Pharmaceuticals LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Neostigmine Methylsulfate (neostigmine methylsulfate)

Snippet

SUPPL AP for NEOSTIGMINE METHYLSULFATE (NEOSTIGMINE METHYLSULFATE)